FDA grants emergency authorization for Seegene COVID-19 test

2020 04 22 21 29 7952 Virus Smash Korea Flag Ball 400

South Korean firm Seegene has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Allplex 2019-nCOV assay.

Seegene already has sold more than 10 million of its real-time reverse transcription polymerase chain reaction (RT-PCR) test for SARS-CoV-2 in more than 60 countries around the world. Allplex is designed to identify three different target genes (E, RdRP, and N genes) in a single reaction tube, which allows for enhanced accurate results and throughput for high volume testing.

With the FDA's EUA designation, Seegene expects U.S. laboratories to adopt the test for SARS-CoV-2.

Page 1 of 23
Next Page